Practice Parameter: Corticosteroid treatment of Duchenne dystrophy: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society
Neurology Moxley et al.
64: 13
Data Supplement
Five tables; five Word documents.
Files in this Data Supplement:
E1
-
Table 1. Double blind randomized controlled trials of prednisone/prednisolone in Duchenne Muscular Dystrophy (class I studies); Word documents.
E2
-
Table 2. Weight gain in Duchenne Muscular Dystrophy patients after 6 and 18 months of
placebo or prednisone (1.5, 0.75, and 0.3 mg/kg/d) treatment; Word document.
E3
-
Table 3. Open trials and case reports of prednisone treatment in Duchenne Muscular Dystrophy (class III and IV studies); Word document.
E4
-
Table 4. Deflazacort (DF) treatment in Duchenne Muscular Dystrophy; Word document.
E5
-
Table 5. Weight gain in Duchenne Muscular Dystrophy patients after 2-5 years of Deflazacort vs. placebo treatment; Word document.